Boston Partners Sells 1,004,496 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Boston Partners cut its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 38.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,631,076 shares of the medical equipment provider’s stock after selling 1,004,496 shares during the quarter. Boston Partners owned approximately 0.82% of Zimmer Biomet worth $172,312,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of ZBH. Stonebridge Financial Group LLC purchased a new stake in Zimmer Biomet in the fourth quarter worth about $25,000. Dunhill Financial LLC lifted its holdings in Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 218 shares during the period. Brooklyn Investment Group purchased a new stake in Zimmer Biomet in the third quarter worth about $35,000. Kentucky Trust Co purchased a new stake in Zimmer Biomet in the fourth quarter worth about $39,000. Finally, OFI Invest Asset Management purchased a new stake in Zimmer Biomet in the fourth quarter worth about $40,000. 88.89% of the stock is owned by institutional investors.

Insider Activity

In other news, SVP Lori Winkler sold 1,443 shares of the business’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares of the company’s stock, valued at $915,379.20. The trade was a 14.13 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.95% of the company’s stock.

Zimmer Biomet Trading Up 0.9 %

NYSE:ZBH opened at $112.78 on Wednesday. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 12 month low of $97.69 and a 12 month high of $133.90. The company has a market cap of $22.45 billion, a PE ratio of 25.34, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04. The company has a 50 day simple moving average of $106.18 and a two-hundred day simple moving average of $106.88.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the prior year, the firm posted $2.20 earnings per share. Research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.85%. The ex-dividend date is Monday, March 31st. Zimmer Biomet’s payout ratio is 21.57%.

Analysts Set New Price Targets

ZBH has been the subject of several research analyst reports. Stifel Nicolaus raised their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a report on Friday, February 7th. Raymond James lowered their target price on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Royal Bank of Canada lowered their target price on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Finally, JMP Securities reiterated a “market outperform” rating and set a $140.00 target price on shares of Zimmer Biomet in a report on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.